Bromide

Bromide

SCHEMBL20184792

[Br-].c1ccc(CN2CCC[N+]3=C2CCCCC3)cc1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.53
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
SIGMAR1 Q99720 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
TSHR P16473 1/20 0.36
HRH3 Q9Y5N1 3/20 0.36
POLB P06746 2/20 0.36
LMNA P02545 1/20 0.36
CYP2D6 P10635 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP2C9 P11712 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29876820 0.90 L3MBTL1 (0.47) L3MBTL1KMT2AMEN1DDB1CRBN
SCHEMBL20184780 0.82 L3MBTL1 (0.40) L3MBTL1NPC1RAB9ATSHRLMNA
SCHEMBL809412 0.70
SCHEMBL28946777 0.69 L3MBTL1 (0.65) L3MBTL1KMT2AMEN1DDB1CRBN
SCHEMBL7269112 0.69 L3MBTL1 (1.00) L3MBTL1KMT2AMEN1DDB1CRBN
SCHEMBL9212361 0.69 L3MBTL1 (1.00) L3MBTL1KMT2AMEN1DDB1CRBN
SCHEMBL1626076 0.69 L3MBTL1 (1.00) L3MBTL1KMT2AMEN1DDB1CRBN
SCHEMBL610772 0.69 L3MBTL1 (1.00) L3MBTL1KMT2AMEN1DDB1CRBN
SCHEMBL11490206 0.68 L3MBTL1 (0.64) L3MBTL1KMT2AMEN1DDB1CRBN
Hydrochloric Acid SCHEMBL12494696 0.68 L3MBTL1 (0.97) L3MBTL1KMT2AMEN1DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3327002-B1 ACID-RESISTANT BASE AND/OR RADICAL GENERATOR, AND CURABLE RESIN COMPOSITION CONTAINING SAID BASE AND/OR RADICAL GENERATOR FUJIFILM WAKO PURE CHEMICAL CORP (JP) 2020-08-19 EP disclosed
US-10428015-B2 Acid-resistant base and/or radical generator, and curable resin composition containing said base and/or radical generator FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2019-10-01 US disclosed
US-20190002403-A1 ACID-RESISTANT BASE AND/OR RADICAL GENERATOR, AND CURABLE RESIN COMPOSITION CONTAINING SAID BASE AND/OR RADICAL GENERATOR FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2019-01-03 US disclosed
EP-3327002-A1 ACID-RESISTANT BASE AND/OR RADICAL GENERATOR, AND CURABLE RESIN COMPOSITION CONTAINING SAID BASE AND/OR RADICAL GENERATOR Wako Pure Chemical Industries, Ltd. (JP) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428015-B2 Acid-resistant base and/or radical generator, and curable resin composition containing said base and/or radical generator REV1, RER1, CBR1 ACHE 3826/4885L3MBTL1 1943/4885KMT2A 1530/4885
US-20190002403-A1 ACID-RESISTANT BASE AND/OR RADICAL GENERATOR, AND CURABLE RESIN COMPOSITION CONTAINING SAID BASE AND/OR RADICAL GENERATOR REV1, RER1, CBR1 ACHE 3826/4885L3MBTL1 1943/4885KMT2A 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.